Deborah DeRyckere

Sep 25, 2024 | nature.com | Justus M. Huelse |Swati Bhasin |Sunil Raikar |Stephen Frye |Deborah DeRyckere |Juhye Yim

AbstractTAM-family tyrosine kinases (TYRO3, AXL and MERTK) are potential cancer therapeutic targets. In previous studies MERTK inhibition in the immune microenvironment was therapeutically effective in a B-cell acute leukemia (B-ALL) model. Here, we probed anti-leukemia immune mechanisms and evaluated roles for TYRO3 and AXL in the leukemia microenvironment.